Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody
- PMID:19028829
- DOI: 10.1177/1352458508099139
Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody
Abstract
Objective: Because Asian patients with opticospinal multiple sclerosis (OSMS) frequently have anti-aquaporin-4 (AQP4) antibody, complement-mediated disruption of astrocyte foot processes is proposed but not yet proven. We aimed to clarify whether complement consumption occurs at relapse in anti-AQP4 antibody-positive patients.
Methods: We analyzed serum CH50, C3, C4, and C-reactive protein (CRP) levels and their relation to clinical phases in 118 MS patients with or without anti-AQP4 antibody. Serum CH50 levels were higher in 24 patients with anti-AQP4 antibody than in 39 OSMS and 54 conventional form of MS (CMS) patients without anti-AQP4 antibody at relapse (Pcorr<0.05) but not in remission. The frequency of hypercomplementemia at relapse was also higher in anti-AQP4 antibody-positive patients than in anti-AQP4 antibody-negative CMS patients (70.4% vs 29.0%, Pcorr<0.05). C3 and C4 levels did not differ significantly among the three groups at relapse. In patients with anti-AQP4 antibody, the coexistence of hypercomplementemia and high CRP values was more common at relapse than in the remission phase (36.0% vs 10.5%, P<0.05). In patients with extensive central nervous system lesions, hypercomplementemia was significantly more common in anti-AQP4 antibody-positive patients than anti-AQP4 antibody-negative ones (88.9% vs 16.7%, P<0.01). We consider that hypercomplementemia in anti-AQP4 antibody-positive patients may reflect a systemic inflammatory reaction at relapse.
Similar articles
- Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F, Ohyagi Y, Kira J.Matsuoka T, et al.Brain. 2007 May;130(Pt 5):1206-23. doi: 10.1093/brain/awm027. Epub 2007 Apr 17.Brain. 2007.PMID:17439988
- Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients.Watanabe A, Matsushita T, Doi H, Matsuoka T, Shigeto H, Isobe N, Kawano Y, Tobimatsu S, Kira J.Watanabe A, et al.J Neurol Sci. 2009 Jun 15;281(1-2):34-40. doi: 10.1016/j.jns.2009.02.371. Epub 2009 Apr 1.J Neurol Sci. 2009.PMID:19339021
- Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese.Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, Yoshiura T, Nakao Y, Ishizu T, Kira JI.Matsushita T, et al.Mult Scler. 2009 Jul;15(7):834-47. doi: 10.1177/1352458509104595. Epub 2009 May 22.Mult Scler. 2009.PMID:19465451
- [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].Misu T, Fujihara K, Itoyama Y.Misu T, et al.Brain Nerve. 2008 May;60(5):527-37.Brain Nerve. 2008.PMID:18516975Review.Japanese.
- Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders.Kira J.Kira J.J Neurol Sci. 2011 Dec 15;311(1-2):69-77. doi: 10.1016/j.jns.2011.08.043. Epub 2011 Sep 29.J Neurol Sci. 2011.PMID:21962794Review.
Cited by
- Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy.Wang Y, Wu A, Chen X, Zhang L, Lin Y, Sun S, Cai W, Zhang B, Kang Z, Qiu W, Hu X, Lu Z.Wang Y, et al.BMC Neurol. 2014 Dec 20;14:246. doi: 10.1186/s12883-014-0246-4.BMC Neurol. 2014.PMID:25526927Free PMC article.
- Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery.Thoman ME, McKarns SC.Thoman ME, et al.Metabolites. 2020 Sep 18;10(9):374. doi: 10.3390/metabo10090374.Metabolites. 2020.PMID:32961928Free PMC article.Review.
- Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.Chamberlain JL, Huda S, Whittam DH, Matiello M, Morgan BP, Jacob A.Chamberlain JL, et al.J Neurol. 2021 May;268(5):1643-1664. doi: 10.1007/s00415-019-09498-4. Epub 2019 Sep 3.J Neurol. 2021.PMID:31482201Review.
- AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.Jarius S, Wildemann B.Jarius S, et al.Nat Rev Neurol. 2010 Jul;6(7):383-92. doi: 10.1038/nrneurol.2010.72.Nat Rev Neurol. 2010.PMID:20639914Review.
- Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions.Cheng C, Jiang Y, Chen X, Dai Y, Kang Z, Lu Z, Peng F, Hu X.Cheng C, et al.BMC Neurol. 2013 Jul 3;13:72. doi: 10.1186/1471-2377-13-72.BMC Neurol. 2013.PMID:23819854Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous